Ajanta Pharma tumbles on US FDA import alert
DSIJ Intelligence / 24 Jan 2017
BSE has sought clarification from Ajanta Pharma on January 24 regarding media reports stating Ajanta Pharma has received import alert from the US Food and Drug Administration (USFDA) for its Paithan unit at Aurangabad. However, Ajanta Pharma has not issued any clarification regarding on the same.
BSE has sought clarification from Ajanta Pharma on January 24 regarding media reports stating Ajanta Pharma has received import alert from the US Food and Drug Administration (USFDA) for its Paithan unit at Aurangabad. However, Ajanta Pharma has not issued any clarification regarding on the same.
Ajanata Pharma has witnessed block deal on NSE amounting to Rs 17.66 crore in first hour of trading session on January 24. Besides, Ajanta Pharma will declare its Q3FY17 results on Tuesday.
The share price of Ajanta Pharma declined 14.36 per cent on the bourses in early trades and is trading at Rs 1718 on an intra-day basis. The stock has recovered soon and at 11 p.m. is down about just 3.79 per cent. The company’s management is expected to clarify on the US FDA issue after declaration of Q3FY17 results.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.